The following is an excerpt.
Venture capital interest in funding gene therapies and the companies that develop them has dramatically increased judging by a recent spurt of activity, a lot of due diligence, a few deals announced, and a few more in the works and expected to be announced soon.
What does all that activity mean? First, there’s enough clinical data out there to validate the concept of gene therapy. The more speculative venture capital investors, rather than the pharmaceutical industry, are realizing the potential of this and are getting into the game.
View the original article here: Is This Gene Therapy’s Breakout Moment?
- “What is gene threapy?” Genetics Home Reference, U.S. National Library of Medicine
- “Super Metabolism? Disabling Plin2 Gene Prevents Obesity In Mice,” Science 2.0